We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Analytics Firm Pulls Back on Drug Revenue Projections
Analytics Firm Pulls Back on Drug Revenue Projections
Patent expirations, biosimilars and uncertainty around the Trump administration’s drug policies will create a pricing squeeze in the drug industry, according to a new analysis.